NCT04884763 - Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions

Temporomandibular Disorder

Interventions

DRUG

Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments

Erenumab-aooe (EREN) 140 mg s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments

DRUG

Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments

Placebo (EREN-P) s.c. administered at baseline and weeks 4, 8, 12 and 16 for a total of five treatments

Trial Locations (1)

Indiana University School of Dentistry, Oral Health Research Institute, Indianapolis